The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis
De Savi, C., Pape, A., Cumming, J.G., Ting, A., Smith, P.D., Burrows, J.N., Mills, M., Davies, C., Lamont, S., Milne, D., Cook, C., Moore, P., Sawyer, Y., Gerhardt, S.(2011) Bioorg Med Chem Lett 21: 1376-1381
- PubMed: 21300546 
- DOI: https://doi.org/10.1016/j.bmcl.2011.01.036
- Primary Citation of Related Structures:  
3Q2G, 3Q2H - PubMed Abstract: 
Two series of N-hydroxyformamide inhibitors of ADAM-TS4 were identified from screening compounds previously synthesised as inhibitors of matrix metalloproteinase-13 (collagenase-3). Understanding of the binding mode of this class of compound using ADAM-TS1 as a structural surrogate has led to the discovery of potent and very selective inhibitors with favourable DMPK properties. Synthesis, structure-activity relationships, and strategies to improve selectivity and lower in vivo metabolic clearance are described.
Organizational Affiliation: 
Respiratory and Inflammation Research Area, AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK. chris.desavi2@astrazeneca.com